Navigation Links
Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results
Date:8/4/2011

MISSISSAUGA, Ontario, Aug. 4, 2011 /PRNewswire/ --

  • 2011 Second Quarter Total Revenue $609 million, including $40 million related to Trobalt milestone
  • Total pro forma revenue growth for the combined company was approximately 27%
  • Excluding the impact of foreign exchange, acquisitions and milestones, pro forma organic growth was approximately 4%
  • Also excluding impact from Diastat and Efudex, pro forma organic growth for the combined company was approximately 7%
  • 2011 Second Quarter GAAP EPS $0.17; Cash EPS $0.73,
  • Includes $0.06 gain from Cephalon investment
  • 2011 Second Quarter GAAP Cash Flow from Operations was $227 million; Adjusted Cash Flow from Operations was $260 million  
  • 2011 Cash EPS Guidance raised to $2.70 - $3.00

  • Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces second quarter financial results for 2011.

    “The second quarter once again demonstrated the strength of our diversified business model,” stated J. Michael Pearson, chairman and chief executive officer.  “While the organic growth in our U.S. operations faced a number of headwinds this quarter, such as a tough comparison to the second quarter of 2010 when Legacy Biovail product sales were at unusually high levels, coupled with lower than expected results delivered by partnered Legacy Biovail generic products, we still delivered solid pro forma organic growth.  We remain confident that our full year pro forma organic growth should be approximately 8 percent due in part to the strong performance from our businesses in Europe, Latin America, Canada and Australia. In addition, we are pleased to report that our cash flow from operations generation was particularly robust this quarter, demonstrating the solid execution of our
    '/>"/>

    SOURCE Valeant Pharmaceuticals International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

    Related medicine technology :

    1. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
    2. Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta™ in Canada
    3. Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics
    4. Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.
    5. Valeant Pharmaceuticals Agrees to Acquire Dermik
    6. Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™
    7. Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results
    8. Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction
    9. Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011
    10. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
    11. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... September 1, 2015 BerGenBio AS ... announces that it has appointed Hilde Furberg ... to its Board of Directors, effective immediately. ... experience in pharma and biotech and is currently Senior ... company. Previously her role was Vice President and General ...
    (Date:9/1/2015)... 1, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... that its affiliate has entered into a collaboration ... an exclusive license to develop and commercialize brodalumab. ... monoclonal antibody in development for patients with moderate-to-severe ... Valeant will hold the exclusive rights to develop ...
    (Date:8/31/2015)... PHOENIX , Aug. 31, 2015  DICOM ... announced today that it was recognized as a ... Radiology software.  The awards are sponsored ... and related professionals in the medical imaging industry.  ... for radiology professionals to acknowledge the contributions of ...
    Breaking Medicine Technology:BerGenBio Appoints Non-Executive Directors 2Valeant And AstraZeneca To Partner On Brodalumab 2Valeant And AstraZeneca To Partner On Brodalumab 3Valeant And AstraZeneca To Partner On Brodalumab 4DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2
    ... 2012   Syndax Pharmaceuticals, Inc. and Ventana Medical ... an agreement to develop a companion diagnostic assay to ... treatment with erlotinib and Syndax,s proprietary lead molecule entinostat.  ... Ventana, a world leader and innovator of tissue-based diagnostic ...
    ... (Nasdaq: VRNM ), a leading industrial biotechnology ... enzymes, today announced the introduction of VEREFLOW™ alpha-amylase, a ... drilling operations.  This high performance enzyme effectively removes filter ... on the face of the wellbore, the hole drilled ...
    Cached Medicine Technology:Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat 2Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat 3Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat 4Verenium Launches Second Enzyme Product for Oilfield Services 2Verenium Launches Second Enzyme Product for Oilfield Services 3
    (Date:9/1/2015)... NV (PRWEB) , ... September 01, 2015 , ... ... or Self-Directed Care is, how to access caregivers and what to look for ... valuable and pertinent information. , Founded in 2006 in Canoga Park, CA by ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... it has established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. ... This rapidly-growing alliance is dedicated to the provision of quality addiction treatment ...
    (Date:9/1/2015)... ... September 01, 2015 , ... The integration ... patients directly from Practice Perfect to FOTO enabling cost and time savings, reducing ... , Steven Presement, President of Practice Perfect, stated "FOTO is a natural extension ...
    (Date:9/1/2015)... ... ... Elizabeth Callahan, MD, founder and medical director of SkinSmart Dermatology® , ... filler treatment for volume loss in the hands. RADIESSE provides an immediate volumizing effect ... delivering smooth, natural-looking results that can last up to one year in most patients. ...
    (Date:9/1/2015)... ... ... Routines… every family has them. Whether it’s a morning routine, meal time routine or ... too. Here are three reasons why routines can be beneficial for a child: , ... is implemented into a child’s schedule, they are able to anticipate what will happen ...
    Breaking Medicine News(10 mins):Health News:AdvantagePlusCaregivers.com® Launches New Website for Corporate and Franchisee Locations in 3 States 2Health News:MAP Health Management Launches the MAP Recovery Network 2Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Back into the Swing of Things: How Family Routines Benefit Children 2
    ... the 66th Annual Meeting of the American Academy ... ... AGI Dermatics presented,clinical research that indicates the 8-oxo-guanine DNA glycosylase (OGG1),encapsulated ... DNA repair, reducing MMP-1 secretion and increasing,collagen production in UV irradiated ...
    ... Uroplasty, Inc. (Amex:,UPI), a medical device company ... for the treatment of voiding dysfunction,announced today ... minimally invasive nerve stimulation device, designed for,office-based ... be,featured in three presentations at the Society ...
    ... Feb. 11 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ:,NRMX; TSX: ... 2008, Dr.,Francesco Bellini, Neurochem,s Chairman, President and Chief ... of the new,nutraceutical business, will present Neurochem,s strategy ... be held at the Waldorf-Astoria, in New York,(NY). ...
    ... bedside manner as better informed patients make ever-increasing demands ... in clinical decisions that directly affect their care. ... Related Research, Dr. J. Bohannon Mason of the Orthocarolina ... at the changes in society, the population and technology ...
    ... incidence of malignancy, so women with this condition can ... to a new study by a team of researchers ... A fibroadenoma is a benign growth of the breast ... usually associated with breast cancer, and are often diagnosed ...
    ... 2008 Researchers at Pulmonary Associates today announced ... for Emphysema) Trial, an international, multi-center clinical trial ... a new, minimally invasive option for those suffering ... airway bypass, a catheter-based bronchoscopic procedure designed to ...
    Cached Medicine News:Health News:AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair 2Health News:AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair 3Health News:Studies on Urgent(R) PC to be Presented at the 2008 Society of Urologic Nurses and Associates Annual Symposium 2Health News:Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live 2Health News:Doctor who? Are patients making clinical decisions? 2Health News:Study finds patients with complex fibroadenomas can avoid surgery 2Health News:Researchers at Pulmonary Associates to study airway bypass procedure for severe emphysema 2
    FLEXILOG spare part....
    Complete calibration kits are available for both pH and manometry systems....
    Flexilog custom medical carts are configured to suite the requirements of FLEXILOG motility system users. With locking wheels and storage drawers, our carts are suitable for any care provider in any ...
    ... kit for convenient pH catheter calibration., ,pH ... any procedure. The Alpine Calibration kit contains ... water for your convenience. Simply cut the ... catheters to soak. No measuring or pouring! ...
    Medicine Products: